CellmAbs

About:

CellmAbs provides research and development services on novel anti-cancer treatments.

Top Investors: Portugal Ventures, Bionova Capital

Description:

CellmAbs is a NOVA University of Lisbon spin-off company that was founded in 2019 with the funding of two of Portugal's top Life Science Venture Capital firms. CellmAbs is a rapidly expanding biotech firm with an international, experienced team that has developed multiple preclinical candidates targeting solid tumors based on a world-class understanding of cancer-specific glycan targets.v

Total Funding Amount:

$1.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lisbon, Lisboa, Portugal

Founded Date:

2019-06-05

Contact Email:

info(AT)cellmabs.com

Founders:

Nuno Prego Ramos, Paula Videira

Number of Employees:

1-10

Last Funding Date:

2019-10-25

IPO Status:

Private

Industries: